Cancer immunotherapy targeting immune checkpoints has exhibited promising clinical outcomes in many cancers, but it offers only limited benefits for pancreatic cancer (PC). Cancer stem cells (CSCs), a minor subpopulation of cancer cells, play important roles in tumor initiation, progression, and drug resistance. Accumulating evidence suggests that CSCs employ immunosuppressive effects to evade immune system recognition. However, the clinical implications of the associations among CD8+ T cells infiltration, programmed death receptor ligand-1 (PD-L1) expression, and CSCs existence are poorly understood in PC. Immunostaining and quantitative analysis were performed to assess CD8+ T cells infiltration, PD-L1 expression, and their relationship w...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
SummaryPancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality....
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a 9% survival rate and rising ...
Programmed death-1 (PD-1), a key immune checkpoint molecule, has been developed as an oncotherapy ta...
progression, maintain the CSCs population, and reduce therapeutic effects. The objective of this stu...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
The tumor microenvironment (TME) plays a vital role in the development, progression, and metastasis ...
Abstract Background The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains poor due to the...
<div><p>Objective</p><p>The immune response to pancreatic ductal adenocarcinoma (PDA) may play a rol...
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenoc...
Cancer stem cells (CSCs) have been identified as a subpopulation of stem-like cancer cells with the ...
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a poorly immunogenic cancer type that co...
Immunosuppression is an important factor for the poor prognosis of pancreatic ductal adenocarcinoma ...
AbstractNo systemic therapy is effective against pancreatic cancer (PC). Pancreatic cancer stem cell...
Pancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality. Stem c...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
SummaryPancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality....
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a 9% survival rate and rising ...
Programmed death-1 (PD-1), a key immune checkpoint molecule, has been developed as an oncotherapy ta...
progression, maintain the CSCs population, and reduce therapeutic effects. The objective of this stu...
The high progression rate of Pancreatic Ductal Adenocarcinoma (PDAC) depends on intrinsic genetic an...
The tumor microenvironment (TME) plays a vital role in the development, progression, and metastasis ...
Abstract Background The prognosis of pancreatic ductal adenocarcinoma (PDAC) remains poor due to the...
<div><p>Objective</p><p>The immune response to pancreatic ductal adenocarcinoma (PDA) may play a rol...
Immunotherapy, including PD-1/PD-L1 agonists, has shown limited efficacy in pancreatic ductal adenoc...
Cancer stem cells (CSCs) have been identified as a subpopulation of stem-like cancer cells with the ...
Pancreatic ductal adenocarcinoma (PDAC) is considered to be a poorly immunogenic cancer type that co...
Immunosuppression is an important factor for the poor prognosis of pancreatic ductal adenocarcinoma ...
AbstractNo systemic therapy is effective against pancreatic cancer (PC). Pancreatic cancer stem cell...
Pancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality. Stem c...
BackgroundWe investigated the correlation between pancreatic ductal adenocarcinoma patient prognosis...
SummaryPancreatic adenocarcinoma is currently the fourth leading cause for cancer-related mortality....
Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer with a 9% survival rate and rising ...